Jan 7, 2026 10:22AM RBC Capital on 4D Molecular Therapeutics (FDMT): 'Story Remains On Track for Late-Stage Execution in wAMD and Pipeline Growth'

Nov 11, 2025 08:39AM 4D Molecular Therapeutics (FDMT) PT Raised to $32 at RBC Capital

Nov 10, 2025 05:01PM 4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q3 EPS

Nov 7, 2025 04:28AM Morgan Stanley Upgrades 4D Molecular Therapeutics (FDMT) to Equalweight

Oct 31, 2025 09:20AM 4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners

Oct 21, 2025 09:11AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)

Aug 11, 2025 11:34AM Goldman Sachs Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Aug 11, 2025 11:33AM 4D Molecular Therapeutics (FDMT) PT Lowered to $16 at Leerink Partners

Aug 11, 2025 10:54AM 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 25c

Jul 2, 2025 04:07PM 4D Molecular Therapeutics (FDMT) Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025 07:30PM 4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q1 EPS

May 1, 2025 08:01AM 4D Molecular Therapeutics Inc. (FDMT) Announces RMAT Designation Granted by FDA for 4D-150 for DME

Feb 10, 2025 02:30PM 4D Molecular Therapeutics (FDMT) PT Lowered to $40 at Jefferies

Feb 10, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Jan 13, 2025 06:20AM 4D Molecular Therapeutics (FDMT) PT Lowered to $27 at Leerink Partners

Jan 13, 2025 04:43AM BMO Capital Downgrades 4D Molecular Therapeutics (FDMT) to Market Perform

Jan 10, 2025 08:07AM 4D Molecular Therapeutics (FDMT) Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

Nov 21, 2024 04:25AM Morgan Stanley Starts 4D Molecular Therapeutics (FDMT) at Underweight

Sep 20, 2024 06:46AM Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)

Sep 19, 2024 08:14AM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)

Sep 19, 2024 08:06AM Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Sep 19, 2024 06:46AM H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Sep 19, 2024 05:25AM Goldman Sachs Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Aug 12, 2024 12:41PM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)

Aug 9, 2024 06:43AM 4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 5c

Jul 22, 2024 06:24AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)

Jul 18, 2024 08:56AM 4D Molecular Therapeutics (FDMT) PT Lowered to $40 at BMO Capital

Jul 17, 2024 01:19PM 4D Molecular Therapeutics tumbles following mid-stage clinical study results

Jul 17, 2024 01:07PM Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview

Jun 26, 2024 05:40AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)

Jun 10, 2024 08:58AM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)